Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells.

Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells.

Item
http://www.wikidata.org/entity/Q39451669
Cisplatin-induced caspase activation mediates PTEN cleavage in ovarian cancer cells: a potential mechanism of chemoresistanceModeling nasopharyngeal carcinoma in three dimensionsCudraflavone C Induces Tumor-Specific Apoptosis in Colorectal Cancer Cells through Inhibition of the Phosphoinositide 3-Kinase (PI3K)-AKT PathwayJerantinine A induces tumor-specific cell death through modulation of splicing factor 3b subunit 1 (SF3B1)Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.Zoledronic acid reverses cisplatin resistance in nasopharyngeal carcinoma cells by activating the mitochondrial apoptotic pathwayPhosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression.[Zn(phen)(O,N,O)(H2O)] and [Zn(phen)(O,N)(H2O)] with O,N,O is 2,6-dipicolinate and N,O is L-threoninate: synthesis, characterization, and biomedical properties.Improved antitumor effect of ionizing radiation in combination with rapamycin for treating nasopharyngeal carcinoma.Norcantharidin induce apoptosis in human nasopharyngeal carcinoma through caspase and mitochondrial pathway.Asplatin enhances drug efficacy by altering the cellular response.Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells.ECRG4 acts as a tumor suppressor and as a determinant of chemotherapy resistance in human nasopharyngeal carcinoma.
P2860

Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells.

Item
http://www.wikidata.org/entity/Q39451669
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells.
@en
Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells.
@nl
type
label
Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells.
@en
Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells.
@nl
prefLabel
Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells.
@en
Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P356
P1433
P1476
Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells.
@en
P2093
P304
P31
P356
10.1016/J.CANLET.2011.09.025
P407
P433
P478
P577
P698